Peter Awad, Mark Awad, John Awad

Introduction

Few medical specialities have experienced such profound transformation over the past three decades as ophthalmology. Diseases that once carried a prognosis of inevitable blindness can now often be stabilised for many years through advances in diagnostics, pharmacotherapy and surgery. Anti-VEGF therapy has revolutionised the management of neovascular age-related macular degeneration (AMD), reducing rates of legal blindness that were once considered unavoidable (1). Similarly, modern glaucoma management has substantially slowed disease progression for many patients through earlier diagnosis, improved medical therapies, laser treatment and surgical innovation (2). National diabetic eye screening programmes combined with advances in retinal laser therapy and intravitreal pharmacotherapy have dramatically reduced blindness from diabetic retinopathy (3). More recently, gene therapy has demonstrated that inherited retinal diseases, once regarded as untreatable, may also become chronic conditions requiring ongoing specialist care rather than inevitable causes of visual decline (4).

These advances deserve celebration, yet they have also created an important paradox. Success in preserving vision has resulted in a rapidly expanding population of patients living longer with chronic eye disease. Rather than completing treatment and being discharged, many patients now enter prolonged pathways of monitoring, repeated interventions and lifelong surveillance. In many respects, ophthalmology has quietly transformed from a speciality centred on restoring or preserving sight through discrete episodes of care to one increasingly responsible for the longitudinal management of chronic disease.

This transformation has received relatively little attention. Discussion surrounding increasing waiting lists, workforce shortages and clinic capacity often focuses on operational challenges rather than their underlying cause. However, these pressures are not simply the result of demographic change or healthcare funding constraints. They are, at least in part, the product of the speciality’s own success. Every patient whose vision is preserved through effective treatment is also a patient who may require continuing care for years or decades thereafter.

The purpose of this commentary is not to argue that therapeutic success has created a problem, but rather that it has changed the responsibilities of ophthalmology. As blindness becomes increasingly preventable across many common eye diseases, the next challenge for this speciality is to ensure that long-term care remains sustainable, equitable and centred on patients’ needs.

From Acute Intervention to Chronic Disease Management

Historically, much of ophthalmic practice revolved around treating acute pathology or performing definitive surgical intervention. Cataract surgery restored vision within a relatively short episode of care, retinal detachment surgery aimed to preserve vision following an acute event, and glaucoma management focused largely on preventing progression through periodic review. Although long-term follow-up has always existed for certain conditions, chronic disease management was not the defining feature of the speciality.

This landscape has changed substantially. The widespread adoption of OCT scans has enabled earlier diagnosis across multiple diseases, while increasingly effective treatments have improved long-term visual outcomes well beyond what was previously achievable. Patients diagnosed with glaucoma in their 6th decade may now retain useful vision throughout their lifetime, but this often requires decades of surveillance. Patients with AMD frequently receive repeated intravitreal injections over many years, transforming a previously blinding disease into a chronic condition requiring continuous management. Similar patterns are emerging in inherited retinal disease and ocular inflammation, where advances in therapy increasingly shift the emphasis from treating irreversible decline to maintaining long-term stability.

In this context, the traditional distinction between ophthalmology as a predominantly procedural speciality and specialities managing chronic diseases becomes increasingly blurred. Ophthalmologists are no longer simply preventing blindness; They are supporting patients throughout prolonged disease trajectories.

The Success Paradox

Medicine typically defines success by improved survival or reduced morbidity. In ophthalmology, success has rightly been measured by reductions in blindness and visual impairment. However, preserving vision changes the demands placed upon healthcare systems. Patients who previously experienced irreversible disease progression now remain under long-term specialist review. As treatments improve, prevalence increases because patients live longer with their condition even when incidence remains stable.

This phenomenon is well recognised in other areas of medicine. Advances in oncology have created growing populations of cancer survivors requiring long-term follow-up. Improvements in HIV therapy transformed a once fatal disease into a chronic condition managed over decades. Cardiology has witnessed similar transitions following advances in the treatment of heart failure and myocardial infarction. Ophthalmology is undergoing a comparable evolution, although this shift is less frequently acknowledged.

Importantly, this should not be viewed negatively; the growing demand for ophthalmic care represents lives lived with preserved vision rather than blindness avoided only temporarily. Nevertheless, recognising this paradox is essential because it changes the question facing the speciality. The challenge is no longer simply developing more effective treatments. Increasingly, it is determining how those treatments can be delivered safely and sustainably over a patient’s lifetime.

What should success look like next?

The next era of innovation in ophthalmology may not be defined solely by new drugs, devices or surgical techniques. Equally important will be innovations and how long-term care is organised. Digital imaging, virtual clinics, multidisciplinary care, community partnerships, home monitoring technologies and artificial intelligence all have potential roles. Not because they replace clinicians, but because they may enable healthcare systems to deliver increasingly complex longitudinal care without compromising quality.

Ultimately, the greatest achievement of modern ophthalmology has been enabling patients to retain vision for longer than ever before. The speciality’s next responsibility is to ensure that these patients continue to receive the lifelong care that therapeutic success has made possible.

Conclusion

Modern ophthalmology stands at an important point in its evolution. Therapeutic advances have fundamentally altered the natural history of many eye diseases, transforming blindness into chronic disease management for countless patients. This remarkable achievement should be celebrated, yet success has also expanded the responsibilities of the speciality. Preventing blindness is no longer sufficient if healthcare systems cannot provide sustainable lifelong care for those whose vision has been preserved. The future of ophthalmology will therefore depend not only on scientific discovery, but also on developing models of care capable of supporting an ageing population living longer with chronic eye disease. The next great innovation in ophthalmology may not be another breakthrough therapy, but ensuring that the benefits of existing therapies remain accessible throughout a patient’s lifetime.

References

1. Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., Kim, R. Y., & MARINA Study Group (2006). Ranibizumab for neovascular age-related macular degeneration. The New England journal of medicine, 355(14), 1419–1431. https://doi.org/10.1056/NEJMoa054481
2. Heijl, A., Leske, M. C., Bengtsson, B., Hyman, L., Bengtsson, B., Hussein, M., & Early Manifest Glaucoma Trial Group (2002). Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of ophthalmology (Chicago, Ill. : 1960), 120(10), 1268–1279.
3. Scanlon P. H. (2017). The English National Screening Programme for diabetic retinopathy 2003-2016. Acta diabetologica, 54(6), 515–525. https://doi.org/10.1007/s00592-017-0974-1
4. Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z. F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., Cross, D., Marshall, K. A., Walshire, J., Kehoe, T. L., Reichert, H., Davis, M., Raffini, L., George, L. A., Hudson, F. P., Dingfield, L., … Maguire, A. M. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet (London, England), 390(10097), 849–860. https://doi.org/10.1016/S0140-6736(17)31868-8